Relixir Pharmaceuticals Private Limited
Relixir Pharmaceuticals Private Limited is a Private Indian company incorporated in 2011 and based in Telangana, India. Relixir Pharmaceuticals Private Limited operates in Pharmaceuticals & Chemicals (NIC 24100) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Relixir Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 22 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 23 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | +19d | filed |
| MGT-7 | FY2022-23 | 22 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Relixir Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 226741484 | State Bank of India(Bank) | ₹9.96 Cr | 04 Jul 2022 | Open |
| 806844544 | HDFC Bank Ltd(Bank) | ₹22.37 Cr | 19 Sep 2021 | Open |
| 361942525 | Kotak Mahindra Bank Ltd(Bank) | ₹21.48 Cr | 04 Jul 2022 | Satisfied |
| 432145058 | Axis Bank Ltd(Bank) | ₹11.29 Cr | 12 Mar 2022 | Open |
| 251058533 | ICICI Bank Ltd(Bank) | ₹6.37 Cr | 12 Mar 2020 | Open |
| 372220441 | Axis Bank Ltd(Bank) | ₹12.06 Cr | 19 Sep 2019 | Satisfied |
Charge IDs, lenders & amounts for Relixir Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
Locked| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| FY2024-25 | ₹28.50 Cr | ₹-27.81 L | ₹12.29 Cr | ₹34.88 Cr | 115 |
| FY2023-24 | ₹25.98 Cr | ₹-25.17 L | ₹23.92 Cr | ₹39.35 Cr | 359 |
| FY2022-23 | ₹24.23 Cr | ₹-1.07 Cr | ₹19.91 Cr | ₹40.52 Cr | 282 |
| FY2021-22 | ₹17.35 Cr | ₹-77.91 L | ₹7.40 Cr | ₹22.66 Cr | 34 |
Audited financials & ratios for Relixir Pharmaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Detailed Financials
Locked| Line item | FY2024-25 | FY2023-24 | FY2022-23 | FY2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ₹28.50 Cr | ₹25.98 Cr | ₹24.23 Cr | ₹17.35 Cr |
| Other income | ₹47.33 L | ₹90.90 L | ₹21.10 L | ₹69.36 L |
| Total income | ₹28.97 Cr | ₹26.88 Cr | ₹24.44 Cr | ₹18.04 Cr |
| Total expenses | ₹29.33 Cr | ₹27.21 Cr | ₹25.82 Cr | ₹19.04 Cr |
| Profit before tax | ₹-36.16 L | ₹-32.72 L | ₹-1.39 Cr | ₹-1.01 Cr |
| Profit / (Loss) after tax | ₹-27.81 L | ₹-25.17 L | ₹-1.07 Cr | ₹-77.91 L |
| Balance sheet | ||||
| Equity / Net worth | ₹12.29 Cr | ₹23.92 Cr | ₹19.91 Cr | ₹7.40 Cr |
| Borrowings | ₹4.76 Cr | ₹3.49 Cr | ₹5.12 Cr | ₹8.32 Cr |
| Current liabilities | ₹12.09 Cr | ₹8.55 Cr | ₹8.80 Cr | ₹9.09 Cr |
| Total liabilities | ₹22.59 Cr | ₹15.43 Cr | ₹20.60 Cr | ₹15.26 Cr |
| Current assets | ₹14.70 Cr | ₹21.26 Cr | ₹22.19 Cr | ₹11.35 Cr |
| Cash & equivalents | ₹1.77 Cr | ₹6.83 Cr | ₹4.35 Cr | ₹3.44 Cr |
| Total assets | ₹34.88 Cr | ₹39.35 Cr | ₹40.52 Cr | ₹22.66 Cr |
| Employees | 115 | 359 | 282 | 34 |
Audited financials & ratios for Relixir Pharmaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Compounded Annual Growth Rate
Locked| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue | ₹28.50 Cr | +28.2% | +19.4% | +12.2% |
| Profit after Tax | ₹-27.81 L | +31.1% | -3.7% | +14.7% |
| Net Worth | ₹12.29 Cr | -9.8% | +11.4% | +22.0% |
| Employees | 115 | +15.3% | +1.6% | +6.1% |
Audited financials & ratios for Relixir Pharmaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Financial Ratios
Locked| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| FY2024-25 | ₹28.50 Cr | ₹-27.81 L | -0.98% | +15.54% | -2.26% | -0.80% | 0.39 | ₹24.78 L |
| FY2023-24 | ₹25.98 Cr | ₹-25.17 L | -0.97% | -8.18% | -1.05% | -0.64% | 0.15 | ₹7.24 L |
| FY2022-23 | ₹24.23 Cr | ₹-1.07 Cr | -4.42% | -1.71% | -5.38% | -2.64% | 0.26 | ₹8.59 L |
| FY2021-22 | ₹17.35 Cr | ₹-77.91 L | -4.49% | +3.30% | -10.53% | -3.44% | 1.12 | ₹51.03 L |
Audited financials & ratios for Relixir Pharmaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 4,09,28,843 | 87.47% |
| Institutional Investors | 3 | 17,31,686 | 3.70% |
| Public & Others | 24 | 41,32,721 | 8.83% |
Promoter, institutional & public holding for Relixir Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
164 peersExternal data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.